Table IV.

Results of an adjusted indirect comparison between the efficacy of infliximab and adalimumab or infliximab and golimumab in terms of clinical response

Variable	6–8 weeks	52–54 weeks
	Clinical response (RR (95% CI))	Clinical response (RR (95% CI))
Infliximab 5 mg vs. adalimumab 160/80 mg
Infliximab [37], [38] vs. adalimumab [31], [32], [39–41]	1.04 (0.70–1.53) p > 0.05	2.46 (0.74–8.16) p > 0.05
Infliximab 5 mg vs. adalimumab 80/40 mg
Infliximab [37], [38] vs. adalimumab [31], [32]	1.13 (0.76–1.68) p > 0.05	NA
Infliximab 5 mg vs. adalimumab 80/40 mg and 80/160 mg
Infliximab [37], [38] vs. adalimumab [31], [32], [39–41]	NA	4.28 (1.12–16.31) p = 0.0331
Infliximab 5 mg vs. golimumab 200/100 mg
Infliximab [37], [38] vs. golimumab [42]	0.95 (0.63–1.43) p > 0.05	NA
Infliximab 5 mg vs. golimumab 100 mg
Infliximab [37], [38] vs. golimumab [43]	NA	2.22 (0.67–7.33) p > 0.05
Infliximab 5 mg vs. golimumab 50 mg
Infliximab [37], [38] vs. golimumab [43]	NA	2.04 (0.62–6.69) p > 0.05